Metronidazol Polpharma (Metronidazole)

Metronidazole enters anaerobic bacteria and protozoa and is reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, leading to cell death. The drug selectively targets organisms that thrive in low‑oxygen environments, sparing most aerobic cells.

The dosage of Metronidazol Polpharma is determined by the prescribing clinician based on the specific infection, severity and patient characteristics. Typical regimens vary, and the prescriber will provide detailed instructions on the amount, frequency and duration of therapy.

Safety data for metronidazole in pregnancy are limited, and the product should be used only when clearly needed. It is excreted in breast milk, so caution is advised for nursing mothers. The prescriber should weigh potential benefits against possible risks before initiating therapy.

To order, submit an enquiry on the Metronidazol Polpharma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metronidazole is a first‑line nitroimidazole antibiotic widely recommended for bacterial vaginosis because of its proven efficacy against anaerobic organisms. Alternatives such as clindamycin or tinidazole may be used, but metronidazole offers a well‑established safety profile and is often preferred for its oral and vaginal formulations.

Store Metronidazol Polpharma below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date. No special refrigeration is required for this vaginal formulation.

Metronidazol Polpharma is applied directly to the vagina, typically as a cream, gel or suppository, according to the prescriber’s instructions. The patient should follow the recommended duration of treatment and avoid sexual intercourse or tampon use if advised, to ensure optimal therapeutic effect.

Serious adverse events, although rare, include seizures, severe skin reactions such as Stevens‑Johnson syndrome, peripheral neuropathy and anaphylaxis. Patients should seek immediate medical attention if they experience neurological symptoms, widespread rash, swelling, difficulty breathing or any signs of an allergic reaction.

Metronidazol Polpharma should be avoided in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe liver impairment, those who consume alcohol heavily, and pregnant or breastfeeding women unless the benefits outweigh the risks.